Kidney Transplant Failure and Rejection Clinical Trial
Official title:
Predicting Prognostic Factors in Kidney Transplantation: A Machine Learning Approach to Enhance Outcome Prediction
NCT number | NCT06394596 |
Other study ID # | 2022-1276 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2023 |
Est. completion date | February 1, 2024 |
Verified date | April 2024 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Kidney transplantation (KT) is the most effective treatment for end-stage renal disease, offering improved quality of life and long-term survival. However, predicting transplant survival and assessing prognostic factors is complex due to the multifaceted nature of patient variables and individualized treatments. Traditional methods have fallen short in their predictive accuracy. This study aims to develop machine learning algorithms capable of parsing extensive clinical data to identify key prognostic indicators that can potentially forecast survival rates for KT recipients. By incorporating baseline characteristics of donors and recipients, the model strives to unearth patterns linking donor and recipient profiles, thereby offering insights into modifiable factors that could influence postoperative outcomes. The goal is to provide a tool that aids clinicians in improving the prognosis and quality of life for KT recipients.
Status | Completed |
Enrollment | 4077 |
Est. completion date | February 1, 2024 |
Est. primary completion date | January 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients who have received kidney transplantation (including multiple times of transplantation) at this hospital. - Patients who have listened to and understood a detailed explanation of this study, and have voluntarily decided to participate and provided written consent. Exclusion Criteria: - Patients who are receiving a multi-organ transplantation (e.g. simultaneous pancreas and kidney transplantation, simultaneous heart and kidney transplantation) |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Sung Shin | Asan Institute for Life Sciences, Korea Health Industry Development Institute |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 5-year graft survival | The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04057742 -
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
|
||
Recruiting |
NCT03465397 -
Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients
|
Phase 4 | |
Completed |
NCT03437577 -
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05282966 -
Assessment of QSantâ„¢ for Underlying Allograft Rejection
|
||
Recruiting |
NCT04388930 -
The Microbiota in Kidney Donation and Transplantation
|
||
Completed |
NCT03611621 -
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
|
||
Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|
||
Completed |
NCT04019353 -
Cf-DNA Assay During Treatment of Acute Rejection
|
||
Active, not recruiting |
NCT05806749 -
Immunological Tolerance in Patients With Mismatched Kidney Transplants
|
Phase 1 | |
Recruiting |
NCT04936282 -
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)
|
Phase 4 | |
Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT04526431 -
Tacrolimus Pharmacokinetic Subpopulations
|
||
Active, not recruiting |
NCT03511560 -
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
|
Phase 4 | |
Recruiting |
NCT03438773 -
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
|
Phase 1 | |
Completed |
NCT05388955 -
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
|
||
Completed |
NCT04413916 -
MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
|
||
Completed |
NCT03466775 -
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
|
N/A | |
Active, not recruiting |
NCT04733131 -
Long-term Outcomes After Conversion to Belatacept
|
||
Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04154267 -
Protocol Biopsies in High-risk Renal Transplant Recipients
|
N/A |